Skip to content
User

Daniel Loeb

Third Point

Daniel Loeb Thermo Fisher Scientific Inc stake

total: 588

Third Point TMO trades

Total transactions:
7
New positions:
3
Sold out:
3
Reduced:
1
Held since:
2025 Q4
Held for:
1 quarter
Latest activity:
2026 Q1
According to 2026 Q2 report, Daniel Loeb doesn't hold any Thermo Fisher Scientific Inc (TMO) shares. Third Point has held TMO since at least 2013 Q2 with about 2.50M shares in our earliest available record. Daniel Loeb later completely sold out the position and invested in Thermo Fisher Scientific Inc again in 2025 Q4. Since at least 2013 Q2, Third Point has made 6 more transactions.

When did Daniel Loeb sell Thermo Fisher Scientific Inc (TMO)?

Daniel Loeb sold off the entire Thermo Fisher Scientific Inc (TMO) position in 2026 Q1.

Estimated cost basis*

Weighted AVG buy price:
$579.45
Weighted AVG sell price:
$579.45

Daniel Loeb's historical trades in Thermo Fisher Scientific Inc

7 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q1
0.00%
0
$579.45
-100% (-50,000)
-0.4%
2025 Q4
0.40%
50,000
$579.45
$28,972,500
new
+0.4%
2025 Q1
0.00%
0
$520.23
-100% (-350,000)
-2.45%
2024 Q4
2.45%
350,000
$520.23
$182,080,500
new
+2.45%
2013 Q4
0.00%
$92.15
-100% (-1,550,000)
2013 Q3
3.50%
$92.15
-38.00% (-950,000)
2013 Q2
4.80%
$84.63
new or own*
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.